Researchers found differences in gut bacteria between children with autism and typically developing children but caution that more research is needed to clarify these associations and their therapeutic potential.
After Phase 3 win, Arrowhead’s RNAi chases Ionis to market entry in rare genetic disorder
Arrowhead Pharmaceuticals’ RNAi treatment has succeeded in a registrational test in patients with an ultra-rare lipid metabolism disorder, bolstering plans for a regulatory filing that